End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.25 CNY | +5.69% | +7.41% | -17.33% |
Apr. 29 | TECON BIOLOGY Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 10 | Tecon Biology's Pig Sales Revenue Climbs 12% in March | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.79 for the current period. Therefore, the company is undervalued.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.33% | 1.37B | - | ||
-5.94% | 266B | A- | ||
-3.51% | 93.75B | C+ | ||
+6.16% | 40.42B | B- | ||
-1.60% | 39.92B | B- | ||
+7.31% | 39.47B | B- | ||
-18.07% | 29.26B | B- | ||
-7.67% | 28.39B | A | ||
+12.84% | 25.04B | A- | ||
-5.93% | 23.52B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 002100 Stock
- Ratings TECON BIOLOGY Co.LTD